Schmid John P. 4/A

What Happened
John P. Schmid, a director of First Tracks Biotherapeutics, received equity awards on May 12, 2026: 7,000 stock options and 2,500 restricted stock units (RSUs). Both awards are reported as acquisitions at $0.00 (standard for grants/derivatives); the filing shows no cash paid. This is an award/grant transaction (code A) rather than an open-market buy or sale. The Form 4 was amended (filed June 12, 2026) to correct the amounts originally reported.

Key Details

• Transaction date: May 12, 2026; Form 4 amendment filed June 12, 2026 (original Form 4 filed May 14, 2026).
• Awards: 7,000 stock options; 2,500 RSUs. Reported acquisition price: $0.00 (grant).
• Shares owned after transaction: Not specified in the information provided in this summary.
• Footnotes of note:
  • RSUs: each RSU converts to one share upon settlement for no consideration (F1). RSUs vest 100% on the date of the issuer’s 2027 annual meeting, subject to continued service (F2).
  • Options: vest 1/12 of total shares monthly beginning June 12, 2026 until fully vested, subject to continued service (F3).
• Amendment note: The June 12, 2026 filing corrects prior amounts to reflect 7,000 options and 2,500 RSUs originally granted on May 12, 2026.

Context
These awards are compensation grants (not exercises or sales). RSUs represent a contingent right to receive shares at vesting; options grant the right to buy shares later subject to vesting. The filing does not indicate any immediate exercise or sale of shares. Awards to directors are common as part of pay and do not by themselves indicate a personal purchase or sale decision.